EUVIMEDEUVIMED entdecken
Crossref

Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)

Harshal Deshmukh, Emmanuel Ssemmondo, Kazeem Adeleke, Shiva Mongolu, Mo Aye, Steve Orme, Daniel Flanagan, Prakash Abraham, Claire Higham, Thozhukat Sathyapalan, UK Acromegaly Register Study (UKAR) Group

Clinical Endocrinology · 2024

DOI: 10.1111/cen.15112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Harshal Deshmukh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Allam Diabetes Centre, Hull University Teaching Hospitals NHS Trust, Hull, UK. Hauptthemen laut MEDLINE: Acromegaly, Remission Induction, Registries. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to understand the effect of time to remission of acromegaly on survival in people living with acromegaly. Design, Patients and Measurement This cross‐sectional study used data from the UK Acromegaly Register. We considered remission of acromegaly growth hormone controlled at ≤2 μg/L following the diagnosis of acromegaly. We used the accelerated failure time model to assess the effect of time to remission on survival in acromegaly.

Results

The study population comprises 3569 individuals with acromegaly, with a median age of diagnosis of 47.3 (36.5–57.8) years, 48% females and a majority white population (61%). The number of individuals with the first remission of acromegaly was 2472, and the median time to first remission was 1.92 (0.70–6.58) years. In this study, time to first remission in acromegaly was found to have a significant effect on survival ( p < .001); for every 1‐year increase in time to first remission, there was a median 1% reduction in survival in acromegaly. In an analysis adjusted for covariates, the survival rate was 52% higher ( p < .001) in those who underwent surgery as compared to those who did not have surgery, 18% higher ( p = .01) in those who received treatment with somatostatin analogues (SMA) as compared to those with dopamine agonists and 21% lower ( p < .001) in those who received conventional radiotherapy as compared to those who did not receive radiotherapy.

Conclusion

In conclusion, this population‐based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyRemission InductionRegistriesHumansFemaleMaleMiddle AgedAdultCross-Sectional StudiesUnited KingdomHuman Growth HormoneTime Factors

Stichwörter der Autor:innen

acromegalygrowth hormonepituitary

Substanzen

Human Growth Hormone

Autor:innen und Institutionen

  • Allam Diabetes Centre, Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • University of Hull, Hull, UK.
  • Leeds Teaching Hospitals NSH Trust, Leeds, UK.
  • University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • NHS Grampian, Aberdeen, UK.
  • Department of Endocrinology, Christie Hospital NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, UK.

Zitieren

APA

Deshmukh, H., Ssemmondo, E., Adeleke, K., Mongolu, S., Aye, M., Orme, S., Flanagan, D., Abraham, P., Higham, C., Sathyapalan, T., & UK Acromegaly Register Study (UKAR) Group (2024). Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR). Clinical Endocrinology. https://doi.org/10.1111/cen.15112

Vancouver

Deshmukh H, Ssemmondo E, Adeleke K, Mongolu S, Aye M, Orme S, et al. Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR). Clinical Endocrinology. 2024. doi:10.1111/cen.15112

BibTeX
@article{Deshmukh2024,
  author = {Deshmukh, Harshal and Ssemmondo, Emmanuel and Adeleke, Kazeem and Mongolu, Shiva and Aye, Mo and Orme, Steve and Flanagan, Daniel and Abraham, Prakash and Higham, Claire and Sathyapalan, Thozhukat and UK Acromegaly Register Study (UKAR) Group, UK Acromegaly Register Study (UKAR) Group},
  title = {Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)},
  journal = {Clinical Endocrinology},
  year = {2024},
  doi = {10.1111/cen.15112}
}
Kostenlos starten →